February 14, 2023
Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Read More
February 9, 2023 Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering
RADNOR, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven …
Continue reading “Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering”

March 28, 2022 Aculys Pharma Closes US$24 Million Series B Financing
Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Fujisawa City, Kanagawa Prefecture, Representative Director and CEO: Kazunari Tsunaba), a new biopharmaceutical company focused on the development and …
Continue reading “Aculys Pharma Closes US$24 Million Series B Financing”

March 10, 2022 Catalys Pacific Calls for Economical Disengagement from Russian Industry
Catalys Pacific would like to inform that we have signed onto an open letter to call for the global business community to economically disengage from …
Continue reading “Catalys Pacific Calls for Economical Disengagement from Russian Industry”

April 6, 2021 Mineralys Therapeutics Closes $40 Million Series A Funding
PHILADELPHIA, PA, April 6, 2021 — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific, announced today that the Company completed a …
Continue reading “Mineralys Therapeutics Closes $40 Million Series A Funding”